ES2163730T3 - Derivados espirocetales y su uso como agentes terapeuticos. - Google Patents

Derivados espirocetales y su uso como agentes terapeuticos.

Info

Publication number
ES2163730T3
ES2163730T3 ES97903437T ES97903437T ES2163730T3 ES 2163730 T3 ES2163730 T3 ES 2163730T3 ES 97903437 T ES97903437 T ES 97903437T ES 97903437 T ES97903437 T ES 97903437T ES 2163730 T3 ES2163730 T3 ES 2163730T3
Authority
ES
Spain
Prior art keywords
pct
spirocetal
derivatives
therapeutic agents
date aug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97903437T
Other languages
English (en)
Inventor
Jason Matthew Elliott
Fintan Kelleher
Christopher John Swain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2163730T3 publication Critical patent/ES2163730T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), EN LA QUE R 1 , R 2 , R 4 , R 5 Y R 6 REPRESENTAN UNA VARIEDAD DE SUSTITUYENTES; R 3 REPRESE NTA UN GRUPO HETEROCICLICO AROMATICO DE 5 O 6 ELEMENTOS OPCIONALMENTE SUSTITUIDO QUE CONTIENE 1, 2, 3 O 4 HETEROATOMOS, SELECCIONADO DEL NITROGENO, OXIGENO Y AZUFRE. R 9A Y R 9B REPRESENTAN CADA UNO, INDEPENDIENTEMENTE, HIDROGENO O ALQUILO C 1-4 , O R 9A Y R 9B ESTAN UNIDOS DE MODO QUE , JUNTO CON LOS ATOMOS DE CARBONO A LOS QUE ESTAN UNIDOS, FORMAN UN ANILLO C 5-7 ; M ES CERO, 1, 2 O 3; Y N ES CERO, 1, 2 O 3; CON LA CONDICION DE QUE LA SUMA TOTAL DE M Y N SEA 2O 3; O A UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS. LOS COMPUESTOS SON DE USO PARTICULAR EN EL TRATAMIENTO O PREVENCION DEL DOLOR, INFLAMACIONES, MIGRAÑA, EMESIS Y NEURALGIA POSTHERPETICA.
ES97903437T 1996-02-15 1997-02-12 Derivados espirocetales y su uso como agentes terapeuticos. Expired - Lifetime ES2163730T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9603137.2A GB9603137D0 (en) 1996-02-15 1996-02-15 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2163730T3 true ES2163730T3 (es) 2002-02-01

Family

ID=10788765

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97903437T Expired - Lifetime ES2163730T3 (es) 1996-02-15 1997-02-12 Derivados espirocetales y su uso como agentes terapeuticos.

Country Status (9)

Country Link
US (1) US6127365A (es)
EP (1) EP0880528B1 (es)
JP (1) JP2000505442A (es)
AT (1) ATE206428T1 (es)
AU (1) AU716691B2 (es)
DE (1) DE69707104T2 (es)
ES (1) ES2163730T3 (es)
GB (1) GB9603137D0 (es)
WO (1) WO1997030055A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929094A (en) * 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) * 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US6335364B1 (en) * 1998-06-29 2002-01-01 Parker Hughes Institute Synthetic spiroketal pyranes as potent anti-cancer agents
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
AR041386A1 (es) * 2002-09-24 2005-05-18 Combinatorx Inc Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
DE102007010077B4 (de) * 2007-02-28 2010-04-08 RUHR-UNIVERSITäT BOCHUM [1,3]-Dioxane zur Modulation von GABAa-Rezeptoren
ES2794801T3 (es) 2015-10-23 2020-11-19 Esteve Pharmaceuticals Sa Compuestos oxaazaespíricos con actividad contra el dolor
US11425169B2 (en) 2016-03-11 2022-08-23 Netskope, Inc. Small-footprint endpoint data loss prevention (DLP)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE69412067T2 (de) * 1993-01-28 1999-03-25 Merck & Co Inc Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
ATE166650T1 (de) * 1993-03-04 1998-06-15 Pfizer Spiroazacyclischderivate als substanz p antagonisten
CA2163995A1 (en) * 1993-06-07 1994-12-22 Malcolm Maccoss Spiro-substituted azacycles as neurokinin antagonists
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
GB9426103D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
DE69707104D1 (de) 2001-11-08
EP0880528B1 (en) 2001-10-04
EP0880528A1 (en) 1998-12-02
GB9603137D0 (en) 1996-04-17
DE69707104T2 (de) 2002-06-20
JP2000505442A (ja) 2000-05-09
WO1997030055A1 (en) 1997-08-21
US6127365A (en) 2000-10-03
ATE206428T1 (de) 2001-10-15
AU1799297A (en) 1997-09-02
AU716691B2 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
DE69528823T2 (de) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
ES2120170T3 (es) Antagonistas azaciclicos gem-disustituidos de taquiquininas.
EA199900045A1 (ru) Производные спиропиперидина и их использование в качестве терапевтических агентов
DE69616480T2 (de) Piperidinderivate als neurokininantagonisten
ATE247096T1 (de) Tetrahydropyranderivate und deren verwendung als therapeutische mittel
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
PA8447801A1 (es) Derivados del acido hexanoico
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
DE60134874D1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
DE60112055D1 (de) Inhibitoren von gamma-secretase
ATE320432T1 (de) Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
ES2163730T3 (es) Derivados espirocetales y su uso como agentes terapeuticos.
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
DK1242410T3 (da) Nye forbindelser
BG105710A (en) 5ht1 antagonists for antidepressant therapy
TR199901395T2 (xx) Yeni karboksi ikameli siklik karboksamid t�revleri.
MX9603199A (es) Antagonistas de receptores a endotelina.
PL343848A1 (en) Novel benzimidazoles and benzoxazoles
ECSP972326A (es) Derivados de espiro - piperidina y su uso como agentes terapeuticos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 880528

Country of ref document: ES